Sage Therapeutics, Inc.
SAGE · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $31,660 | $14,063 | $12,816 | $11,871 |
| % Growth | 125.1% | 9.7% | 8% | – |
| Cost of Goods Sold | -$55 | $655 | $1,489 | $5,278 |
| Gross Profit | $31,715 | $13,408 | $11,327 | $6,593 |
| % Margin | 100.2% | 95.3% | 88.4% | 55.5% |
| R&D Expenses | $23,917 | $22,759 | $37,021 | $54,576 |
| G&A Expenses | $61,997 | $0 | $54,645 | $53,219 |
| SG&A Expenses | $61,997 | $57,591 | $54,645 | $53,219 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$230 | $513 | $21,855 | $0 |
| Operating Expenses | $85,684 | $80,863 | $113,521 | $107,795 |
| Operating Income | -$53,969 | -$67,455 | -$102,194 | -$101,202 |
| % Margin | -170.5% | -479.7% | -797.4% | -852.5% |
| Other Income/Exp. Net | $4,317 | $5,241 | $6,416 | $7,651 |
| Pre-Tax Income | -$49,652 | -$62,214 | -$95,778 | -$93,551 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$49,652 | -$62,214 | -$95,778 | -$93,551 |
| % Margin | -156.8% | -442.4% | -747.3% | -788.1% |
| EPS | -0.79 | -1.01 | -1.57 | -1.53 |
| % Growth | 21.8% | 35.7% | -2.6% | – |
| EPS Diluted | -0.79 | -1.01 | -1.57 | -1.53 |
| Weighted Avg Shares Out | 62,611 | 61,858 | 60,766 | 61,117 |
| Weighted Avg Shares Out Dil | 62,611 | 61,858 | 60,766 | 61,117 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,323 | $5,223 | $6,398 | $7,642 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $104 | $112 | $129 | $255 |
| EBITDA | -$54,095 | -$67,455 | -$80,211 | -$100,947 |
| % Margin | -170.9% | -479.7% | -625.9% | -850.4% |